| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2009 | WO2009023903A1 Compositions comprising phospholipids |
| 02/26/2009 | WO2009009622A3 Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
| 02/26/2009 | WO2009009531A3 Pyrimidinecarboxamide derivatives for the treatment of hiv infections |
| 02/26/2009 | WO2009008997A3 Treatment of neuropathic pain |
| 02/26/2009 | WO2009006577A3 Compositions and methods for inhibiting ezh2 |
| 02/26/2009 | WO2009006473A3 Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
| 02/26/2009 | WO2009005469A3 The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome |
| 02/26/2009 | WO2009005329A3 Composition comprising starch or dietary fiber from gramineae plant for prevention and treatment of ischemic diseases and degenerative brain diseases |
| 02/26/2009 | WO2009005265A3 Acne therapeutic agent and sebum secernent inhibitor which comprise indole-3-alkylcarbo xylicacid, and kits for photodynamic therapy containing the same |
| 02/26/2009 | WO2009005258A3 Heparin conjugates and methods |
| 02/26/2009 | WO2009004654A3 Modified release dosage form of sulfonylurea compound |
| 02/26/2009 | WO2009003998A3 Antiproliferative compounds based on 5-membered heterocycles |
| 02/26/2009 | WO2009002768A3 Liquid bandage |
| 02/26/2009 | WO2009002440A3 Compositions comprising human egfr-sirna and methods of use |
| 02/26/2009 | WO2009001046A3 [11c]methoxy-radiolabelled 2,3',4,5'-tetramethylstilbene (tms) and its preparation and use |
| 02/26/2009 | WO2008157308A3 A zwitterion solution for low-volume therapeutic delivery |
| 02/26/2009 | WO2008157207A3 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3- cyclopentylpropanenitrile |
| 02/26/2009 | WO2008156833A3 G2a receptor as a therapeutic target |
| 02/26/2009 | WO2008156331A3 Novel use of lignan compounds |
| 02/26/2009 | WO2008156217A3 Pharmaceutical solid preparation comprising benzazepines and production method thereof |
| 02/26/2009 | WO2008155572A3 Fused quinoline derivatives useful as gaba modulators |
| 02/26/2009 | WO2008154402A3 Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| 02/26/2009 | WO2008153318A3 Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof |
| 02/26/2009 | WO2008152421A3 Modification of cytokine levels with glucosylamine compounds |
| 02/26/2009 | WO2008152330A3 Use of 4-phenyl-imidazole-2-thiones as tyrosinase inhibitors for preparing pharmaceutical or cosmetic compositions for treating or preventing pigment disorders |
| 02/26/2009 | WO2008148599A3 Process for obtaining a valsartan salt useful for obtaining valsartan |
| 02/26/2009 | WO2008147483A3 Neurogenic compounds |
| 02/26/2009 | WO2008147480A3 Hydroxamic acid derivatives of 3-phenyl propionic acids useful as thrapeutic agents for treating anthrax poisoning |
| 02/26/2009 | WO2008145759A9 New silver(i) compounds and their use in pharmaceutical compositions for the treatment, prophylaxis and prevention of infections |
| 02/26/2009 | WO2008145095A3 Amino acid-mineral-peptide complex, especially quantum-mechanically modified, as a medicament for the treatment of dementia diseases |
| 02/26/2009 | WO2008144690A3 Compositions and methods for enhancing active agent absorption |
| 02/26/2009 | WO2008143642A3 Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids |
| 02/26/2009 | WO2008141446A8 Amino acid derivatives as calcium channel blockers |
| 02/26/2009 | WO2008140553A3 Mapk/erk kinase inhibitors |
| 02/26/2009 | WO2008137084A3 Diazaquinolones that inhibit prolyl hydroxylase activity |
| 02/26/2009 | WO2008136865A3 (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 02/26/2009 | WO2008130395A3 Desferrithiocin analogue actinide decorporation agents |
| 02/26/2009 | WO2008127307A3 Induction of an immune response against dengue virus using prime-boost approach |
| 02/26/2009 | WO2008125337A3 Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
| 02/26/2009 | WO2008116194A3 Blockers of pore-forming virulence factors and their use as anti-infectives |
| 02/26/2009 | WO2008112313A3 Processes for preparing solid states of o-desmethylvenlafaxine succinate |
| 02/26/2009 | WO2008109724A3 Treatment of cocaine-induced fetal brain injury |
| 02/26/2009 | WO2008109548A3 Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof |
| 02/26/2009 | WO2008109472A9 Nucleic acid compounds for inhibiting pcsk9 gene exprression and uses thereof |
| 02/26/2009 | WO2008097364A3 Use of oritavancin for prevention and treatment of anthrax |
| 02/26/2009 | WO2008096122A3 Progesterone for the prevention of preterm birth |
| 02/26/2009 | WO2008094222A3 Porphyrin catalysts and methods of use thereof |
| 02/26/2009 | WO2008090585A3 Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field |
| 02/26/2009 | WO2008088581A3 Liposome treatment of viral infections |
| 02/26/2009 | WO2008085875A3 R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma) |
| 02/26/2009 | WO2008083226A3 Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| 02/26/2009 | WO2008073961A3 Compounds and methods for modulating the silencing of a polynucleotide of interest |
| 02/26/2009 | WO2008064004A3 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| 02/26/2009 | WO2008051527A3 Sustained release of agents for localized pain management |
| 02/26/2009 | WO2008046538A3 Non-steroid antiphlogistics against coughing |
| 02/26/2009 | WO2008035066A3 Processes for the preparation of ciclesonide and its crystal form |
| 02/26/2009 | WO2008030579A3 Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| 02/26/2009 | WO2008024439A3 4-aminoquinazoline derivatives and methods of use thereof |
| 02/26/2009 | WO2008022761A3 Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders |
| 02/26/2009 | WO2008011071A3 Interactions of hedgehog and liver x receptor signaling pathways |
| 02/26/2009 | WO2008008397A8 Fatty acid pharmaceutical foam |
| 02/26/2009 | WO2008005368A3 Piperazines as p2x7 antagonists |
| 02/26/2009 | WO2007149852A3 Modified factor viii and factor ix genes and vectors for gene therapy |
| 02/26/2009 | WO2007117684A3 Carisoprodol articles and methods |
| 02/26/2009 | WO2007115168A8 Compositions and methods for inhibiting expression of eg5 gene |
| 02/26/2009 | WO2007106111A3 Nanoparticulate and controlled release compositions comprising nilvadipine |
| 02/26/2009 | WO2007094972A3 Cellulite skin treatment methods and compositions |
| 02/26/2009 | WO2007032023A8 A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof |
| 02/26/2009 | WO2007014226A3 Compounds for the treatment of neurodegeneration and stroke |
| 02/26/2009 | WO2006091894A4 New polymeric materials and methods |
| 02/26/2009 | WO2006072951A3 Compositions and methods for regulating apoptosis |
| 02/26/2009 | WO2005110407A3 Nanoparticle dispersion containing lactam compound |
| 02/26/2009 | US20090055941 Novel Neural Cell Specific Promoter And Baculovirus And Method For Gene Delivery |
| 02/26/2009 | US20090054720 Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| 02/26/2009 | US20090054663 Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls |
| 02/26/2009 | US20090054532 Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation |
| 02/26/2009 | US20090054531 Eye drop preparation comprising xanthan gum and terpenoid |
| 02/26/2009 | US20090054530 Methods and Compositions that Enhance Bioavailability of Coenzyme-Q10 |
| 02/26/2009 | US20090054528 Bridged polycyclic compound based compositions for coating oral surfaces in pets |
| 02/26/2009 | US20090054527 Administration of capsaicinoids |
| 02/26/2009 | US20090054526 Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders |
| 02/26/2009 | US20090054525 Selective androgen receptor modulators |
| 02/26/2009 | US20090054524 Methods for identifying and using IKK inhibitors |
| 02/26/2009 | US20090054523 Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases |
| 02/26/2009 | US20090054522 Hair Care Product |
| 02/26/2009 | US20090054521 Zwitterionic compounds and use thereof |
| 02/26/2009 | US20090054520 Oxalic acid derivatives and use thereof as physiological cooling active ingredients |
| 02/26/2009 | US20090054519 Derivatives of monosaccharides as 5-lipoxygenase inhibitors |
| 02/26/2009 | US20090054518 AMPelopsin Unsaturated Sodium Salt Preparation and Applications thereof |
| 02/26/2009 | US20090054517 Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment |
| 02/26/2009 | US20090054516 Composition for treating cancer cells and synthetic method for the same |
| 02/26/2009 | US20090054515 Skin-whitening cosmetic |
| 02/26/2009 | US20090054514 (3-Amino-6-phenyl-benzofuran-2-yl)-(2,4-dichloro-phenyl)-methanone; antiprolifrative, anticarcinogenic, antitumor agent; lymphomas, sarcomas, and leukemias |
| 02/26/2009 | US20090054513 Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
| 02/26/2009 | US20090054512 Use of organic compounds |
| 02/26/2009 | US20090054511 S)-(+)-N-acetyl-2,4,6-tribromo-5-methoxytryptophan methyl ester (4) from (S)-(+)-N-acetyl-5-methoxytryptophan methyl ester; osteoporosis, osteoblast activator |
| 02/26/2009 | US20090054510 Method for identifying compounds for the treatment of depression |
| 02/26/2009 | US20090054509 Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments |
| 02/26/2009 | US20090054508 Igf-1r inhibitor |
| 02/26/2009 | US20090054507 Control of malignant cells by kinase inhibition |